Caplyta is the brand name for lumateperone, an atypical antipsychotic used for schizophrenia and mood disorders in adults. It has U.S. approvals for schizophrenia, bipolar depression (as monotherapy or adjunct with lithium/valproate), and as adjunctive treatment in major depressive disorder. It is an oral prescription medicine.
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' Bysanti for treating schizophrenia and acute bipolar I disorder. The company expects to launch the drug in the third quarter of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05356013 |
Caplyta in Borderline Personality Disorder |
COMPLETED | PHASE2 |
